Haemonine

Haemonine is a prescription intravenous medication whose active ingredient is human coagulation factor IX. It is supplied as a sterile solution for intravenous infusion, with the specific strength not publicly disclosed. Haemonine belongs to the coagulation factor class and is used to replace deficient factor IX in patients with hemophilia B or other factor IX deficiencies. The product is marketed in the European Union region.

Haemonine is indicated for the management of patients with inherited or acquired deficiencies of coagulation factor IX.

- Replacement therapy for hemophilia B (factor IX deficiency). - Perioperative management to prevent bleeding during surgery in patients with factor IX deficiency. - Treatment of acute bleeding episodes in individuals with hemophilia B. - Prophylactic administration to reduce the frequency of spontaneous joint and muscle bleeds.

The safety profile of Haemonine reflects the typical observations for plasma‑derived coagulation factor concentrates.

Common: - Injection site erythema or pain. - Mild headache. - Transient fever. - Nausea or vomiting.

Serious: - Development of inhibitors (antibodies) against factor IX. - Allergic reactions including rash, pruritus, or anaphylaxis. - Thrombotic events such as deep‑vein thrombosis. - Transmission of infectious agents (very rare).

Clinicians should consider several precautions when prescribing Haemonine to ensure safe and effective use.

- Assess baseline factor IX activity and inhibitor status before initiating therapy. - Monitor for signs of allergic reactions during and after infusion. - Use caution in patients with a history of thrombosis or cardiovascular disease. - Adjust dose in patients with renal or hepatic impairment as needed. - Avoid concurrent use of other pro‑coagulant agents unless clinically justified. - Educate patients on recognizing symptoms of inhibitor development.

Haemonine may interact with other medications that affect hemostasis or immune response.

Avoid: - Concomitant use of other factor concentrates or bypassing agents without specialist guidance. - High‑dose pro‑coagulant drugs (e.g., activated prothrombin complex concentrates) that increase thrombotic risk.

Use with caution: - Antifibrinolytic agents such as tranexamic acid, which may enhance clot stability. - Immunosuppressive therapies that could alter inhibitor formation. - Vaccines administered shortly before or after infusion, which may affect immune response.